Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 176

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

High Response Rate to Cisplatin/Etoposide Regimen in Childhood Low-Grade Glioma

Massimino, Maura, Spreafico, Filippo, Cefalo, Graziella, Riccardi, Riccardo, Tesoro-Tess, John David, Gandola, Lorenza, Riva, Daria, Ruggiero, Antonio, Valentini, Laura, Mazza, Elena, Genitori, Lorenzo, Di Rocco, Concezio, Navarria, Piera, Casanova, Michela, Ferrari, Andrea, Luksch, Roberto, Terenziani, Monica, Balestrini, Maria Rosa, Colosimo, Cesare, Fossati-Bellani, Franca·2002·Journal of Clinical Oncology

Abstract

PURPOSE: The aim of this study was to avoid radiotherapy and to induce an objective response in children with low-grade glioma (LGG) using a simple chemotherapy regimen based on cisplatin and etoposide. PATIENTS AND METHODS: Thirty-four children (median age, 45 months) with unresectable LGG were treated with 10 monthly cycles of cisplatin (30 mg/m 2/d on days 1 to 3) and etoposide (150 mg/m 2/d on days 1 to 3). Tumor originated in the visual pathway in 29 patients, in the temporal lobe in two, in the frontal lobe in two, and in the spine in one. Eight children were affected by neurofibromatosis type 1. Objective tumor response and toxicity were evaluated by magnetic resonance imaging and neurologic and functional tests at 3-month intervals. RESULTS: An objective response was obtained in 24 (70%) of 34 patients, whereas the others had stable disease. None of the children were electively irradiated. In 31 previously untreated children, overall survival was 100% and progression-free survival was 78% at 3 years, with a median follow-up of 44 months. Acute toxicity was unremarkable; 28% patients evaluated for acoustic neurotoxicity revealed a loss of perception of high frequencies. CONCLUSION: Cisplatin and etoposide combined treatment is one of the most active regimens for LGG in children and allows avoidance of radiotherapy in the vast majority of patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2002.08.087

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 176

Metadata

Authors
Massimino, M., Spreafico, F., Cefalo, G., Riccardi, R., Tesoro-Tess, J. D., Gandola, L., Riva, D., Ruggiero, A., Valentini, L., Mazza, E., Genitori, L., Di Rocco, C., Navarria, P., Casanova, M., Ferrari, A., Luksch, R., Terenziani, M., Balestrini, M. R., Colosimo, C., & Fossati-Bellani, F.
Venue
Journal of Clinical Oncology
Published
2002-10-15
Volume
20
Issue
20
Pages
4209-4216
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2161551028
Cited by
176
References
1
FWCI
1.86
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High Response Rate to Cisplatin/Etoposide Regimen in Childhood Low-Grade Glioma. https://app.cochat.ai/papers/10.1200/jco.2002.08.087
The paper
Massimino, M., Spreafico, F., Cefalo, G., Riccardi, R., Tesoro-Tess, J. D., Gandola, L., Riva, D., Ruggiero, A., Valentini, L., Mazza, E., Genitori, L., Di Rocco, C., Navarria, P., Casanova, M., Ferrari, A., Luksch, R., Terenziani, M., Balestrini, M. R., Colosimo, C., & Fossati-Bellani, F. (2002). High Response Rate to Cisplatin/Etoposide Regimen in Childhood Low-Grade Glioma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2002.08.087

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.